These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Effects of a potent, non-selective endothelin receptor antagonist, [Thr18, gamma-MeLeu19]-endothelin-1, on the isolated blood vessels.
    Author: Karaki H, Sudjarwo SA, Shimamoto N, Wakimasu M, Fujino M.
    Journal: Biochem Biophys Res Commun; 1995 Jul 17; 212(2):421-7. PubMed ID: 7626056.
    Abstract:
    The endothelin (ET) receptor has been classified as the ETA1, ETA2, ETB1 and ETB2 subtypes. BQ-123 and RES-701-1 are the ETA1 and ETB1 antagonists, respectively, whereas BQ-788 is the ETB1/ETB2 antagonist. To find the ETA2 antagonist, the effects of [Thr18, gamma-MeLeu19]-ET-1 (TM-ET-1) were examined. In the rabbit saphenous vein, contraction induced by ET-1 is due to simultaneous activation of the ETA1, ETA2, ETB1 and ETB2 receptors whereas contraction induced by sarafotoxin S6c is mediated by the ETB1 and ETB2 receptors. Neither BQ-123 nor RES-701-1 inhibited these contractions. TM-ET-1 antagonized the effects of ET-1 and sarafotoxin S6c. In the vein in which the ETB1/ETB2 receptors were desensitized and the ETA1 receptor was inhibited by BQ-123, ET-1 still induced contraction. This contraction was inhibited by TM-ET-1. In the rat aorta with endothelium, ET-3 induced endothelium-dependent relaxation by activating the endothelial ETB1 receptor. TM-ET-1 inhibited the effect of ET-3 without changing the relaxation induced by carbachol. In the rat aorta without endothelium, ET-1 induced contraction by activating the smooth muscle ETA1 receptor. TM-ET-1 inhibited this contraction. These results suggest that TM-ET-1 is a novel antagonist against the ETA2 receptor that also inhibits other types of the ET receptors.
    [Abstract] [Full Text] [Related] [New Search]